“20-30 million dollars in annual revenue.” per Jon Rice at ASM
Currently, with 161.3m market cap, we are less than 10x future annual sales for just Quang Nam. We should be over 30x sales right now. ... We are being artificially held down by the RS 1 for 40 option fear.
The reason biotechs get such a high price to future sales is that there are such huge potential future profits from these drugs. The same holds for KBLB’s potential profit margins.